ESC Premium Access

Poster Session 5 - Atrial fibrillation and oral anticoagulation 1

Event: ESC CONGRESS 2019
Topic: European Society of Cardiology
Session type: Poster Session
Date: 2 September 2019

Congress Session

14 presentations in this session

Oral anticoagulants and their effect on kidneys function, is warfarin safe?

Speaker: Associate Professor T. Novikova (Saint Petersburg, RU)

Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in newly diagnosed non-valvular atrial fibrillation.

Speaker: Doctor L. Bergamaschi (Milan, IT)

Inappropriate dosing of non-vitamin K oral anticoagulants (NOACs) in atrial fibrillation patients in Europe

Speaker: Ms I. Palau (London, GB)

Patients with atrial fibrillation exhibit a systemic prothrombotic state attributable to impaired endogenous fibrinolysis

Speaker: Doctor Y. Gue (Liverpool, GB)

Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study

Speaker: Professor P. Hjemdahl (Stockholm, SE)

Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims

Speaker: Doctor T. Vaitsiakhovich (Berlin, DE)

Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation

Speaker: Associate Professor Z. Hijazi (Uppsala, SE)

HASBLED score, frailty index or comorbidity index for bleeding risk assessment in patients with atrial fibrillation?

Speaker: Professor L. Fauchier (Tours, FR)

Renal function worsening in factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease - insights from the RELOADED study

Speaker: Professor H. Bonnemeier (Kiel, DE)

Uninterrupted and minimally-interrupted direct oral anticoagulant therapy in patients undergoing catheter ablation for atrial fibrillation. An updated meta-analysis

Speaker: Doctor M. Ottoffy (Pecs, HU)

14 speakers from this session

Associate Professor Tatiana Novikova

North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg (Russian Federation)
0 follower

Doctor Luca Bergamaschi

ASST Fatebenefratelli Sacco, Milan (Italy)
0 follower

Ms Isabel Palau

Ipsos Mori, London (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Ying Gue

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)
0 follower

Professor Paul Hjemdahl

Karolinska University Hospital, Stockholm (Sweden)
0 follower

Doctor Tatsiana Vaitsiakhovich

Bayer AG, Berlin (Germany)
0 follower

Associate Professor Ziad Hijazi

Uppsala University, UCR-Uppsala Clinical Research Center, Uppsala (Sweden)
4 presentations
0 follower

Professor Laurent Fauchier

Tours Regional University Hospital, Hospital Trousseau, Tours (France)
12 presentations
1 follower

Professor Hendrik Bonnemeier

University Medical Center of Schleswig-Holstein, Kiel (Germany)
6 presentations
0 follower

Doctor Mate Ottoffy

University of Pecs, Pecs (Hungary)
0 follower

Doctor Jose Paulo Lopes De Almeida

University Hospitals of Coimbra, Coimbra (Portugal)
1 presentation
0 follower

Doctor Michel Zeitouni

Pitie Salpetriere APHP University Hospital, Paris (France)
0 follower

Doctor Akio Hirata

Osaka Police Hospital, Osaka (Japan)
0 follower

Doctor Ana Ruigomez

Spanish Research Center Pharmacoepidemologic (CEIFE), Madrid (Spain)
0 follower

This platform is supported by

logo Novo Nordisk